The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it strong buy, with a mean price target of $10305.
CRH PLC
CRH.L · LSE · GBp · Market cap $58.7B
FAIL · Does not pass the screenPrice as of 9 May 2026Daily close, not a live quoteLast reviewed 191 days ago
Screened 2026-05-09 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price8,790.00 GBp at the 9 May 2026 close
- Fair valueUnder review: its inputs are 190 days old; there is no analyst estimate to cross-check it.
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed9 May 2026 (191 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-05-09).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
CRH PLC holds its Markup at $8,790.00. Consolidating, no directional conviction, held for 8 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 8 days |
| Price at the screen | $8,790.00 |
| Valuation | 2,159.71 trailing · 1,736.13 forward price to earnings |
| Values screen | FAIL · score 10.0 |
Five Screens, Shown in Full
Does not pass. Debt ratio 33.8%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 33.78% | Below 33% | Interest-bearing debt is 33.8% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 7.02% | Below 33% | Cash held in interest-bearing accounts and securities is 7.0% of assets, under the one-third limit. | Pass |
| Receivables | 7.37% | Below 49% | Money owed to the company is 7.4% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.77% | Below 5% | Only 1.8% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
CRH's business is in a permissible area, but its interest-bearing debt is about 34% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CRH.L's ethical verdict changes
Today CRH.L does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Its inputs are 190 days old; there is no analyst estimate to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
ProjectionsWhere our models see it going: no fair-value estimate yet, range not available, dated to the 2026-05-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 1,736.1xexpensive even after accounting for its growth |
| Trailing P/E | 2,159.7xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 4.07 |
| EPS, forward | 5.06 |
| Revenue growth | +6.2%slow but positive growth |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | 15.7%a solid return on shareholder capital |
| FCF yield | 3.13% |
| Dividend yield | 0.01% |
| Debt to equity | 0.77moderate, manageable leverage |
| Market cap | $58.7B |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCRH.L trades on LSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it strong buy, with a mean price target of $10305.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it strong buy, with a mean price target of $10305.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it strong buy, with a mean price target of $10305.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it strong buy, with a mean price target of $10305.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it strong buy, with a mean price target of $10305.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 99%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (11 analysts) rates it strong buy, with a mean price target of $10305.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | TALBOT SIOBHAN | Director | 2,000 | $204,223 | |
| 2026-03-11 | FEARON RICHARD H | Director | 3,800 | $397,062 | |
| 2026-02-24 | BUCKLEY PETER J | Officer | 24,186 | · | |
| 2026-02-24 | SAN AGUSTIN JUAN PABLO | Officer | 27,293 | · | |
| 2026-02-24 | SAN AGUSTIN JUAN PABLO | Officer | 4,422 | · | |
| 2026-02-23 | MINTERN DENIS JAMES | Chief Executive Officer | 14,372 | · | |
| 2026-02-23 | LAKE RANDY | Chief Operating Officer | 73,767 | · | |
| 2026-02-23 | LAKE RANDY | Chief Operating Officer | 17,064 | · | |
| 2026-02-23 | WHEATLEY PHILIP | Officer | 28,466 | · | |
| 2026-02-23 | LANE KRISTIN | Officer | 15,262 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $7,800.00 | -98.9% | · | $11 | -98.9% |
| 2 months | $9,169.58 | -99.0% | $29.16 | $13 | -98.7% |
| 3 months | $9,139.58 | -99.0% | $29.16 | $13 | -98.7% |
| 6 months | $8,679.22 | -99.0% | $56.82 | $17 | -98.3% |
| 1 year | $6,430.80 | -98.6% | $112.15 | $31 | -96.9% |
| 2 years | $6,363.53 | -98.6% | $218.32 | $48 | -95.2% |
| 3 years | $3,986.20 | -97.8% | $343.92 | $108 | -89.2% |
| 5 years | $3,510.06 | -97.5% | $529.34 | $176 | -82.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CRH.L does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.